Hypertension: Issues in control and resistance

Current Hypertension Reports

Volumn 11, Issue 5, 2009, Pages 323-328

  Wofford, Marion R ^a   Minor, Deborah S ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALDOSTERONE; ANABOLIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; BUMETANIDE; CENTRAL STIMULANT AGENT; CHLORTALIDONE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; MINERALOCORTICOID ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; RAMIPRIL; SPIRONOLACTONE; TACROLIMUS; TELMISARTAN; THIAZIDE DIURETIC AGENT; TORASEMIDE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ALCOHOL CONSUMPTION; AORTA COARCTATION; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CUSHING SYNDROME; DRUG INHIBITION; ETHNICITY; FLUID RETENTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERKALEMIA; HYPERTENSION; INTRACRANIAL TUMOR; KIDNEY DISEASE; LIFESTYLE; LIFESTYLE MODIFICATION; MEDICATION ERROR; OBESITY; PATIENT COMPLIANCE; PHEOCHROMOCYTOMA; PRIMARY HYPERALDOSTERONISM; RENOVASCULAR DISEASE; REVIEW; SALT INTAKE; SEX DIFFERENCE; SIDE EFFECT; SLEEP APNEA SYNDROME; SODIUM EXCRETION; THYROID DISEASE; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; WHITE COAT HYPERTENSION; MEDICATION COMPLIANCE; PATHOPHYSIOLOGY; RISK FACTOR; TIME;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; LIFE STYLE; MEDICATION ADHERENCE; RISK FACTORS; TIME FACTORS;

EID: 70349675566     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-009-0055-0     Document Type: Review

References (26)

1. Ong KL, Cheung BM, Man YB, et al.: Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007; 49:69-75.
2. Chobanian AV, Bakris GL, Black HR, et al.: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC report. JAMA 2003, 289:2560-2572.
3. American Heart Association: Heart disease and stroke statistics-2009 update. Circulation 2009, 119:e21-e181.
4. Franco OH, Peeters A, Bonneux L, de Laet C: Blood pressure in adulthood and life expectancy with cardiovascular disease in men and women: Life course analysis. Hypertension 2005, 46:261-262.
5. Ezzati M, Lopez AD, Rodgers A, et al.: Selected major risk factors and global and regional burden of disease. Lancet 2002, 360:1347-1360.
6. Calhoun DA, Jones DA, Textor S, et al.: Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Assoc iation Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008, 51:1403-1419.
7. Lloyd-Jones DM, Evans JC, Larson MG, et al.: Differential control of systolic and diastolic blood pressure: Factors associated with lack of blood pressure control in the community. Hypertension 2000, 36:594-599.
8. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997.
9. Sarafidis PA, Bakris, GL: Resistant hypertension. J Am Coll Cardiol 2008, 52:1749-1757.
10. Pickering TG, White WB, American Society of Hypertension Writing Group: ASH Position Paper: Home and ambulatory blood pressure monitoring. When and how to use self (home) and ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich) 2008, 10:850-855.
11. Pickering TG, Shimbo D, Hass D: Ambulatory blood-pressure monitoring. N Engl J Med 2006, 354:2368-2374.
12. Ogedegbe G: Barriers to optimal hypertension control. J Clin Hypertens (Greenwich) 2008, 10:644-646.
13. Minor DS, Wofford MR, Jones DW: Racial and ethnic differences in hypertension. Curr Atheroscler Rep 2008, 10:121-127.
14. Garrison RJ, Kannel WB, Stokes J 3rd, Castelli WP: Incidence and precursors of hypertension in young adults; the Framingham Offspring Study. Prev Med 1987, 16:235-251.
15. Poirier P, Giles TD, Bray GA, et al.: Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss. Circulation 2006, 113:898-918.
16. Wofford MR, Hall JE: Pathophysiology and treatment of obesity hypertension. Curr Pharm Des 2004, 10:3621-3637.
17. Appel LJ, Brands MW, Daniels SR, et al.: Dietary approaches to prevent and treat hypertension: A scientific statement for the American Heart Association. Hypertension 2006, 47:296-308.
18. Moser M, Setaro JF: Resistant or difficult to control hypertension. N Engl J Med 2006, 355:355-385.
19. Sowers JR, Whaley-Connell A, Epstein M: The emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009, 150:776-783.
20. Calhoun DA, Nishizaka MK, Zaman MA, et al.: Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002, 40:892-896.
21. Pimenta E, Gaddam KK, Oparil S: Mechanisms and treatments of resistant hypertension. J Clin Hypertens (Greenwich) 2008, 10:239-244.
22. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al.: Characterization of resistant hypertension. Arch Intern Med 2008, 168:1159-1164.
23. Logan AC, Perlikowski SM, Mente A, et al.: High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 2001, 19:1-7.
24. Pratt-Ubanama MN, Nishizaka MK, Boedefeld MD, et al.: Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 2007, 131:453-459.
25. Goodfriend TL, Calhoun DA: Resistant hypertension, obesity, and aldosterone. Theory and therapy. Hypertension 2004, 43:518-524.
26. Mann JF, Schmieder RE, McQueen M, et al.: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547-553.